TR201906372T4 - Nano taşıyıcılara ait formülasyonlar ve bunların hazırlanmasına ilişkin yöntemler. - Google Patents

Nano taşıyıcılara ait formülasyonlar ve bunların hazırlanmasına ilişkin yöntemler. Download PDF

Info

Publication number
TR201906372T4
TR201906372T4 TR2019/06372T TR201906372T TR201906372T4 TR 201906372 T4 TR201906372 T4 TR 201906372T4 TR 2019/06372 T TR2019/06372 T TR 2019/06372T TR 201906372 T TR201906372 T TR 201906372T TR 201906372 T4 TR201906372 T4 TR 201906372T4
Authority
TR
Turkey
Prior art keywords
solution
nanocarriers
mixture
drug
formulations
Prior art date
Application number
TR2019/06372T
Other languages
English (en)
Inventor
Doshi Manish
Sherdiwala Divyesh
Sojitra Prakash
Original Assignee
Concept Medical Res Private Limited
Envision Scient Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concept Medical Res Private Limited, Envision Scient Private Limited filed Critical Concept Medical Res Private Limited
Publication of TR201906372T4 publication Critical patent/TR201906372T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624—Nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nano taşıyıcıların hazırlanmasına yönelik bir yöntem ifşa edilmektedir. Yöntem, bir ilaca ait bir organik çözelti ve bir biyolojik maddeye ait bir organik çözelti bir veya daha fazla çözünmüş yüzey aktif maddeye yer veren önceden belirlenmiş bir miktardaki suyla ayrı ayrı karıştırılarak sırasıyla birinci bir karışımın ve ikinci bir karışımın elde edilmesini içermektedir. Daha sonra, birinci karışım ve ikinci karışım ayrı ayrı homojenleştirilerek sırasıyla ilacın nano kristallerine ait bir çözelti ve biyolojik maddenin nano parçacıklarına ait bir çözelti elde edilmektedir. Ardından, ilacın nano kristallerine ait çözelti ve biyolojik maddenin nano parçacıklarına ait çözelti bir ultrasonlu homojenleştirme işlemine birlikte tabi tutularak nano taşıyıcılara ait bir çözelti elde edilmektedir. Daha sonra, nano taşıyıcılara ait çözelti üzerinde bir ara yüzey ekstraksiyonu ve/veya bir diyaliz gerçekleştirilerek nano taşıyıcılar elde edilmektedir. Nano taşıyıcılara ait formülasyonlar da ifşa edilmektedir.
TR2019/06372T 2010-01-18 2011-01-06 Nano taşıyıcılara ait formülasyonlar ve bunların hazırlanmasına ilişkin yöntemler. TR201906372T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN133MU2010 2010-01-18

Publications (1)

Publication Number Publication Date
TR201906372T4 true TR201906372T4 (tr) 2019-05-21

Family

ID=44304741

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/06372T TR201906372T4 (tr) 2010-01-18 2011-01-06 Nano taşıyıcılara ait formülasyonlar ve bunların hazırlanmasına ilişkin yöntemler.

Country Status (9)

Country Link
US (1) US20120321670A1 (tr)
EP (1) EP2525782B1 (tr)
CA (1) CA2786671A1 (tr)
DK (1) DK2525782T3 (tr)
ES (1) ES2726952T3 (tr)
PL (1) PL2525782T3 (tr)
PT (1) PT2525782T (tr)
TR (1) TR201906372T4 (tr)
WO (1) WO2011086574A2 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002989C (en) 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
WO2016044482A1 (en) * 2014-09-17 2016-03-24 Vivacelle Bio, Inc. Stable micelle and/or liposome compositions and uses thereof
CA3050535C (en) 2014-12-15 2021-11-09 Richard Clark Kaufman Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals
CN104586817A (zh) * 2015-02-11 2015-05-06 苏州大学 一种多西他赛固体脂质纳米粒冻干制剂及其制备方法
EP3268043A4 (en) 2015-03-10 2018-12-19 Nanosphere Health Sciences, LLC Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN119431400A (zh) 2020-03-27 2025-02-14 波士顿科学国际有限公司 用于使药物结晶的方法
CN111671982A (zh) * 2020-05-08 2020-09-18 北京永益润成科技有限公司 一种药物涂层组合物及其制备方法
WO2023172347A1 (en) * 2022-03-10 2023-09-14 Nammi Therapeutics, Inc. Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
CN114886855B (zh) * 2022-05-19 2023-10-03 北京柏欧利诺生物科技有限公司 一种雷公藤红素纳米药物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
JP4684991B2 (ja) * 2003-01-31 2011-05-18 ボストン サイエンティフィック リミテッド 薬物添加ナノカプセルを用いる局所的薬物デリバリー
CN1493361A (zh) * 2003-08-29 2004-05-05 上海医药工业研究院 山榆酸甘油酯的脂质纳米粒及其制备方法
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
BRPI0600275A (pt) * 2006-01-03 2007-10-02 Brz Biotecnologia Ltda prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
DE102007061624A1 (de) * 2007-05-31 2009-06-25 Ernst-Moritz-Arndt-Universität Greifswald Verfahren zur Beschichtung von Oberflächen mit Mikro- und Nanopartikeln mit Hilfe von Plasmaverfahren und dessen Verwendung
CN101167699A (zh) * 2007-11-28 2008-04-30 厦门大学 胰岛素口服缓释制剂及其制备方法
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
NZ597308A (en) * 2009-05-29 2013-07-26 Envision Scient Private Ltd Re-establishment of blood flow in blocked human arteries by transferring nano-encapsulated drug through medical devices, designed for the same and releasing the nano- encapsulated drug in human artery with body ph
WO2010140163A2 (en) * 2009-06-02 2010-12-09 Concept Medical Inc. Rejuvenating coronary artery by improving blood flow with the help of insertion of nano-balls (encapsulated nanoparticles) containing therapeutic agents by non implantable device for tissues and thereby providing in tissue release to address the required cell cycle

Also Published As

Publication number Publication date
US20120321670A1 (en) 2012-12-20
ES2726952T3 (es) 2019-10-10
DK2525782T3 (da) 2019-06-11
WO2011086574A2 (en) 2011-07-21
PT2525782T (pt) 2019-06-06
EP2525782A2 (en) 2012-11-28
EP2525782B1 (en) 2019-03-13
PL2525782T3 (pl) 2019-09-30
CA2786671A1 (en) 2011-07-21
WO2011086574A3 (en) 2011-11-10
EP2525782A4 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
TR201906372T4 (tr) Nano taşıyıcılara ait formülasyonlar ve bunların hazırlanmasına ilişkin yöntemler.
Ganesan et al. Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery
Wang et al. Plant exosome-like nanoparticles as biological shuttles for transdermal drug delivery
ES2721325T3 (es) Método para producir de manera estéril partículas de lípido-ácido nucleico
Can et al. Optimization and characterization of chitosan films for transdermal delivery of ondansetron
Mathes et al. The use of skin models in drug development
DK2056681T3 (da) Homofermenterede produkter
CO2017001921A2 (es) Anticuerpos anti-cll-1 e inmunoconjugados
BR112013020992A2 (pt) aparelho e método para isolamento de leucócitos e células tumorosas por meio de filtração
MX2015014312A (es) Metodo para tratar un sustrato hecho de fibras animales con particulas solidas y una formulacion quimica que comprende un colorante.
UA110671C2 (uk) Екстракція полікарбонової кислоти
Ahmad et al. Nanoscale topical pharmacotherapy in management of psoriasis: contemporary research and scope
BRPI0915142A8 (pt) Polipeptídeos, ácido nucleico e usos dos mesmos
Zhan et al. Ethosomes: a promising drug delivery platform for transdermal application
MX2011006771A (es) Metodo de preparacion de una composicion de micelas polimericas que contienen un farmaco pobremente soluble en agua.
GB201121288D0 (en) Functionalised silicon nanoparticles
BRPI1005516A2 (pt) aparelho de decomposição de biomassa e método do mesmo, e sistema de produção de solução de açúcar usando material de biomassa
Zaid Alkilani et al. Development and evaluation of an innovative approach using niosomes based polymeric microneedles to deliver dual antioxidant drugs
Deviatkin et al. Universal flu mRNA vaccine: promises, prospects, and problems
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
Wang et al. Efficient sustained-release nanoparticle delivery system protects nigral neurons in a toxin model of Parkinson’s disease
Zhang et al. State of the art in constructing gas-propelled dissolving microneedles for significantly enhanced drug-loading and delivery efficiency
UA116776C2 (uk) Лікарська форма для продовженого вивільнення діючих речовин
Hagiwara et al. Potential of modulating aldosterone signaling and mineralocorticoid receptor with microRNAs to attenuate diabetic kidney disease
AR074406A1 (es) Celulas madre terapeuticas derivadas de monocitos humanos y un metodo para inducir celulas madre terapeuticas derivadas de monocitos humanos